Geoepidemiological hints about Streptococcus pyogenes strains in relationship with acute rheumatic fever

Autoimmunity Reviews

Volumn 14, Issue 7, 2015, Pages 616-621

  Esposito, Susanna ^a   Bianchini, Sonia ^a   Fastiggi, Michele ^b   Fumagalli, Monica ^a   Andreozzi, Laura ^b   Rigante, Donato ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Acute rheumatic fever; Group A Streptococcus; Streptococcal complication

Indexed keywords

M PROTEIN;

CLINICAL EVALUATION; DEVELOPED COUNTRY; DISEASE ASSOCIATION; DISEASE SURVEILLANCE; EPIDEMIOLOGICAL DATA; FOLLOW UP; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GROUP A STREPTOCOCCAL INFECTION; HUMAN; MEDLINE; METHODOLOGY; NONHUMAN; OBSERVATIONAL STUDY; PHENOTYPIC VARIATION; PREVALENCE; REVIEW; RHEUMATIC FEVER; STREPTOCOCCUS; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; ACUTE DISEASE; COMPLICATION; GENETICS;

ACUTE DISEASE; GENOTYPE; HUMANS; PREVALENCE; RHEUMATIC FEVER; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

EID: 84928929534     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.03.001     Document Type: Review

References (85)

1. Lancefield R.C. A serological differentiation of human and other groups of hemolytic Streptococci. J Exp Med 1933, 57:571-595.
2. Chakravarty S.D., Zabriskie J.B., Gibofsky A. Acute rheumatic fever and streptococci: the quintessential pathogenic trigger of autoimmunity. Clin Rheumatol 2014, 33:893-901.
3. Perricone C., Rinkevich S., Blank M., Landa-Rouben N., Alessandri C., Conti F., et al. The autoimmune side of rheumatic fever. Isr Med Assoc J 2014, 16:654-655.
4. Carapetis J.R., Steer A.C., Mulholland E.K., Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005, 5:685-694.
5. Cunningham M.W. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000, 13:470-511.
6. Lamagni T.L., Darenberg J., Luca-Harari B., Siljander T., Efstratiou A., Henriques-Normark B., et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2008, 46:2359-2367.
7. O'Brien K.L., Beall B., Barrett N.L., Cieslak P.R., Reingold A., Farley M.M., et al. Epidemiology of invasive group A Streptococcus disease in the United States, 1995-1999. Clin Infect Dis 2002, 35:268-276.
8. De Rosa G., Pardeo M., Stabile A., Rigante D. Rheumatic heart disease in children: from clinical assessment to therapeutical management. Eur Rev Med Pharmacol Sci 2006, 10:107-110.
9. Morens D.M., Folkers G.K., Fauci A.S. The challenge of emerging and re-emerging infectious diseases. Nature 2004, 430:242-249.
10. Cunningham M.W. Pathogenesis of group A streptococcal infections and their sequelae. Adv Exp Med Biol 2008, 609:29-42.
11. Henningham A., Barnett T.C., Maamary P.G., Walker M.J. Pathogenesis of group A streptococcal infections. Discov Med 2012, 13:329-342.
12. Burke R.J., Chang C. Diagnostic criteria of acute rheumatic fever. Autoimmun Rev 2014, 13:503-507.
13. Murray R.C., Chennupati S.K. Chronic streptococcal and non-streptococcal pharyngitis. Infect Disord Drug Targets 2012, 12:281-285.
14. Ebell M.H. Diagnosis of streptococcal pharyngitis. Am Fam Physician 2014, 89:976-977.
15. ESCMID Sore Throat Guideline Group, Pelucchi C., Grigoryan L., Galeone C., Esposito S., Huovinen P., et al. Guideline for the management of acute sore throat. Clin Microbiol Infect 2012, 18(Suppl. 1):1-28.
16. Metzgar D., Zampolli A. The M protein of group A Streptococcus is a key virulence factor and a clinically relevant strain identification marker. Virulence 2011, 2:402-412.
17. Lee J.L., Naguwa S.M., Cheema G.S., Gershwin M.E. Acute rheumatic fever and its consequences: a persistent threat to developing nations in the 21st century. Autoimmun Rev 2009, 9:117-123.
18. Kadir I.S., Barker T.A., Clarke B., Denley H., Grötte G.J. Recurrent acute rheumatic fever: a forgotten diagnosis?. Ann Thorac Surg 2004, 78:699-701.
19. De Rosa G., Pardeo M., Rigante D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci 2007, 11:301-308.
20. Carapetis J.R. Rheumatic heart disease in developing countries. N Engl J Med 2007, 357:439-441.
21. Gerber M.A., Baltimore R.S., Eaton C.B., Gewitz M., Rowley A.H., Shulman S.T., et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009, 119:1541-1551.
22. Toor D., Vohra H. Immune responsiveness during disease progression from acute rheumatic fever to chronic rheumatic heart disease. Microbes Infect 2012, 14:1111-1117.
23. Bryant P.A., Smyth G.K., Gooding T., Oshlack A., Harrington Z., Currie B., et al. Susceptibility to acute rheumatic fever based on differential expression of genes involved in cytotoxicity, chemotaxis, and apoptosis. Infect Immun 2014, 82:753-761.
24. DiSciascio G., Taranta A. Rheumatic fever in children. Am Heart J 1980, 99:635-658.
25. Holden M.T., Scott A., Cherevach I., Chillingworth T., Churcher C., Cronin A., et al. Complete genome of acute rheumatic fever-associated serotype M5 Streptococcus pyogenes strain Manfredo. J Bacteriol 2007, 189:1473-1477.
26. Facklam R., Beall B., Efstratiou A., Fischetti V., Johnson D., Kaplan E., et al. Emm typing and validation of provisional M types for group A streptococci. Emerg Infect Dis 1999, 5:247-253.
27. Facklam R.F., Martin D.R., Lovgren M., Johnson D.R., Efstratiou A., Thompson T.A., et al. Extension of the Lancefield classification for group A streptococci by addition of 22 new M protein gene sequence types from clinical isolates: emm103 to emm124. Clin Infect Dis 2002, 34:28-38.
28. Syrogiannopoulos G.A., Grivea I.N., Al-Lahham A., Panagiotou M., Tsantouli A.G., Michoula Ralf René Reinert A.N., et al. Seven-year surveillance of emm types of pediatric Group A streptococcal pharyngitis isolates in Western Greece. PLoS One 2013, 8:e71558.
29. Walker M.J., Barnett T.C., McArthur J.D., Cole J.N., Gillen C.M., Henningham A., et al. Disease manifestations and pathogenic mechanisms of group a Streptococcus. Clin Microbiol Rev 2014, 27:264-301.
30. Bisno A.L., Brito M.O., Collins C.M. Molecular basis of group A streptococcal virulence. Lancet Infect Dis 2003, 3:191-200.
31. Cohen-Poradosu R., Kasper D.L. Group A Streptococcus epidemiology and vaccine implications. Clin Infect Dis 2007, 45:863-865.
32. Dey N., McMillan D.J., Yarwood P.J., Joshi R.M., Kumar R., Good M.F., et al. High diversity of group A Streptococcal emm types in an Indian community: the need to tailor multivalent vaccines. Clin Infect Dis 2005, 40:46-51.
33. Bessen D.E., Carapetis J.R., Beall B., Katz R., Hibble M., Currie B.J., et al. Contrasting molecular epidemiology of group A streptococci causing tropical and nontropical infections of the skin and throat. J Infect Dis 2000, 182:1109-1116.
34. McMillan D.J., Drèze P.A., Vu T., Bessen D.E., Guglielmini J., Steer A.C., et al. Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study. Clin Microbiol Infect 2013, 19:E222-E229.
35. Dinkla K., Talay S.R., Mörgelin M., Graham R.M., Rohde M., Nitsche-Schmitz D.P., et al. Crucial role of the CB3-region of collagen IV in PARF-induced acute rheumatic fever. PLoS One 2009, 4:e4666.
36. Dinkla K., Nitsche-Schmitz D.P., Barroso V., Reissmann S., Johansson H.M., Frick I.M., et al. Identification of a streptococcal octapeptide motif involved in acute rheumatic fever. J Biol Chem 2007, 282:18686-18693.
37. Dinkla K., Rohde M., Jansen W.T., Kaplan E.L., Chhatwal G.S., Talay S.R. Rheumatic fever-associated Streptococcus pyogenes isolates aggregate collagen. J Clin Invest 2003, 111:1905-1912.
38. Tandon R., Sharma M., Chandrashekhar Y., Kotb M., Yacoub M.H., Narula J. Revisiting the pathogenesis of rheumatic fever and carditis. Nat Rev Cardiol 2013, 10:171-177.
39. Musser J.M., Shelburne S.A. A decade of molecular pathogenomic analysis of group A Streptococcus. J Clin Invest 2009, 119:2455-2463.
40. Cunningham M.W. Streptococcus and rheumatic fever. Curr Opin Rheumatol 2012, 24:408-416.
41. Cunningham M.W. Rheumatic fever, autoimmunity, and molecular mimicry: the streptococcal connection. Int Rev Immunol 2014, 33:314-329.
42. Pruksakorn S., Currie B., Brandt E., Phornphutkul C., Hunsakunachai S., Manmontri A., et al. Identification of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci. Int Immunol 1994, 6:1235-1244.
43. Bryant P.A., Robins-Browne R., Carapetis J.R., Curtis N. Some of the people, some of the time: susceptibility to acute rheumatic fever. Circulation 2009, 119:742-753.
44. Lynskey N.N., Lawrenson R.A., Sriskandan S. New understandings in Streptococcus pyogenes. Curr Opin Infect Dis 2011, 24:196-202.
45. Ayoub E.M., Barrett D.J., Maclaren N.K., Krischer J.P. Association of class II human histocompatibility leukocyte antigens with rheumatic fever. J Clin Invest 1986, 77:2019-2026.
46. Smeesters P.R., Drèze P.A., Perez-Morga D., Biarent D., Van Melderen L., Vergison A. Group A Streptococcus virulence and host factors in two toddlers with rheumatic fever following toxic shock syndrome. Int J Infect Dis 2010, 14:e403-e409.
47. Olivier C. Rheumatic fever - is it still a problem?. J Antimicrob Chemother 2000, 45(Suppl.):13-21.
48. Henningham A., Gillen C.M., Walker M.J. Group A streptococcal vaccine candidates: potential for the development of a human vaccine. Curr Top Microbiol Immunol 2013, 368:207-242.
49. Smeesters P.R., Mardulyn P., Vergison A., Leplae R., Van Melderen L. Genetic diversity of group A Streptococcus M protein: implications for typing and vaccine development. Vaccine 2008, 26:5835-5842.
50. Steer A.C., Magor G., Jenney A.W., Kado J., Good M.F., McMillan D., et al. emm and C-repeat region molecular typing of beta-hemolytic Streptococci in a tropical country: implications for vaccine development. J Clin Microbiol 2009, 47:2502-2509.
51. Cole J.N., Henningham A., Gillen C.M., Ramachandran V., Walker M.J. Human pathogenic streptococcal proteomics and vaccine development. Proteomics Clin Appl 2008, 2:387-410.
52. Smeesters P.R., McMillan D.J., Sriprakash K.S., Georgousakis M.M. Differences among group A Streptococcus epidemiological landscapes: consequences for M protein-based vaccines?. Expert Rev Vaccines 2008, 8:1705-1720.
53. Ekelund K., Darenberg J., Norrby-Teglund A., Hoffmann S., Bang D., Skinhoj P., et al. Variations in emm type among group A streptococcal isolates causing invasive or noninvasive infections in a nationwide study. J Clin Microbiol 2005, 43:3101-3109.
54. Espinosa L.E., Li Z., Gomez Barreto D., Calderon Jaimes E., Rodriguez R.S., Sakota V., et al. M protein gene type distribution among groupA streptococcal clinical isolates recovered in Mexico city, Mexico, from 1991 to 2000, and Durango, Mexico, from 1998 to 1999: overlap with type distribution within the United States. J Clin Microbiol 2003, 41:373-378.
55. Liang Y., Liu X., Chang H., Ji L., Huang G., Fu Z., et al. Epidemiological and molecular characteristics of clinical isolates of Streptococcus pyogenes collected between 2005 and 2008 from Chinese children. J Med Microbiol 2012, 61:975-983.
56. Shea P.R., Ewbank A.L., Gonzalez-Lugo J.H., Martagon-Rosado A.J., Martinez-Gutierrez J.C., Rehman H.A., et al. Group A Streptococcus emm gene types in pharyngeal isolates, Ontario, Canada, 2002-2010. Emerg Infect Dis 2011, 17:2010-2017.
57. Wozniak A., Rojas P., Rodriguez C., Undabarrena A., Garate C., Riedel I., et al. M-protein gene-type distribution and hyaluronic acid capsule in group A Streptococcus clinical isolates in Chile: association of emm gene markers with csrR alleles. Epidemiol Infect 2012, 140:1286-1295.
58. Steer A.C., Law I., Matatolu L., Beall B.W., Carapetis J.R. Global emm type distribution of group A Streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 2009, 9:611-616.
59. De Amicis K.M., Freschi de Barros S., Alencar R.E., Postól E., Martins Cde O., Arcuri H.A., et al. Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes. Vaccine 2014, 32:4104-4110.
60. Shulman S.T., Tanz R.R., Dale JB Beall B., Kabat W., Kabat K., North American Streptococcal Pharyngitis Surveillance Group, et al. Seven-year surveillance of North American pediatric group a streptococcal pharyngitis isolates. Clin Infect Dis 2009, 49:78-84.
61. Luca-Harari B., Darenberg J., Neal S., Siljander T., Strakova L., Tanna A., et al. Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 2009, 47:1155-1165.
62. Tamayo E., Montes M., García-Medina G., García-Arenzana J.M., Pérez-Trallero E. Spread of a highly mucoid Streptococcus pyogenes emm 3/ST15 clone. BMC Infect Dis 2010, 10:233.
63. Tamayo E., Montes M., García-Arenzana J.M., Pérez-Trallero E. Streptococcus pyogenes emm-types in northern Spain; population dynamics over a 7-year period. J Infect 2014, 68:50-57.
64. Mengeloglu F.Z., Aktas E., Otlu B., Cömert F., Külah C., Tas E., et al. Evaluation of emm gene types, toxin gene profiles and clonal relatedness of group A streptococci. Bosn J Basic Med Sci 2013, 13:163-169.
65. You Y.H., Song Y.Y., Yan X.M., Wang H.B., Zhang M.H., Tao X.X., et al. Molecular epidemiological characteristics of Streptococcus pyogenes strains involved in an outbreak of scarlet fever in China, 2011. Biomed Environ Sci 2013, 26:877-885.
66. Wu P.C., Lo W.T., Chen S.J., Wang C.C. Molecular characterization of Group A streptococcal isolates causing scarlet fever and pharyngitis among young children: a retrospective study from a northern Taiwan medical center. J Microbiol Immunol Infect 2014, 47:304-310.
67. Dhanda V., Vohra H., Kumar R. Virulence potential of Group A Streptococci isolated from throat cultures of children from north India. Indian J Med Res 2011, 133:674-680.
68. Dhanda V., Vohra H., Kumar R. Group A Streptococcus virulence factors genes in north India & their association with emm type in pharyngitis. Indian J Med Res 2011, 133:110-115.
69. Balaji K., Thenmozhi R., Prajna L., Dhananjeyan G., Pandian S.K. Comparative analysis of emm types, superantigen gene profiles and antibiotic resistance genes among Streptococcus pyogenes isolates from ocular infections, pharyngitis and asymptomatic children in south India. Infect Genet Evol 2013, 19:105-112.
70. Sagar V., Kumar R., Ganguly N.K., Chakraborti A. Comparative analysis of emm type pattern of group A Streptococcus throat and skin isolates from India and their association with closely related SIC, a streptococcal virulence factor. BMC Microbiol 2008, 8:150.
71. Le Hello S., Doloy A., Baumann F., Roques N., Coudene P., Rouchon B., et al. Clinical and microbial characteristics of invasive Streptococcus pyogenes disease in New Caledonia, a region in Oceania with a high incidence of acute rheumatic fever. J Clin Microbiol 2010, 48:526-530.
72. Hraoui M., Boutiba-Ben Boubaker I., Doloy A., Samir E., Ben Redjeb S., Bouvet A. Epidemiological markers of Streptococcus pyogenes strains in Tunisia. Clin Microbiol Infect 2011, 17:63-68.
73. Erdem G., Mizumoto C., Esaki D., Abe L., Reddy V., Effler P.V. Streptococcal emm types in Hawaii: a region with high incidence of acute rheumatic fever. Pediatr Infect Dis J 2009, 28:13-16.
74. Williamson D.A., Moreland N.J., Carter P., Upton A., Morgan J., Proft T., et al. Molecular epidemiology of group A Streptococcus from pharyngeal isolates in Auckland, New Zealand, 2013. N Z Med J 2014, 127:55-60.
75. Alfaresi M.S. Group A, streptococcal genotypes from throat and skin isolates in the United Arab Emirates. BMC Res Notes 2010, 3:94.
76. Kuttner A.G., Krumwiede E. Observations on the effect of streptococcal upper respiratory infections on rheumatic children a three year study. J Clin Invest 1941, 20:273-287.
77. Carapetis J.R., McDonald M., Wilson N.J. Acute rheumatic fever. Lancet 2005, 366:155-168.
78. Stollerman G.H. Rheumatogenic and nephritogenic streptococci. Circulation 1971, 43:915-921.
79. Stollerman G.H. Rheumatogenic streptococci and autoimmunity. Clin Immunol Immunopathol 1991, 61:131-142.
80. Stollerman G.H. Rheumatic fever. Lancet 1997, 349:935-942.
81. Chang C. Cutting edge issues in rheumatic fever. Clin Rev Allergy Immunol 2012, 42:213-237.
82. Ba-Saddik I.A., Munibari A.A., Alhilali A.M., Ismail S.M., Murshed F.M., Coulter J.B., et al. Prevalence of Group A beta-haemolytic Streptococcus isolated from children with acute pharyngotonsillitis in Aden, Yemen. Trop Med Int Health 2014, 19:431-439.
83. Bisno A.L., Berrios X., Quesney F., Monroe D.M., Dale J.B., Beachey E.H. Type-specific antibodies to structurally defined fragments of streptococcal M proteins in patients with acute rheumatic fever. Infect Immun 1982, 38:573-579.
84. Sakata H. Susceptibility and emm type of Streptococcus pyogenes isolated from children with severe infection. J Infect Chemother 2013, 19:1042-1046.
85. Yang P., Peng X., Zhang D., Wu S., Liu Y., Cui S., et al. Characteristics of group A Streptococcus strains circulating during scarlet fever epidemic, Beijing, China, 2011. Emerg Infect Dis 2013, 19:909-915.